New clinical data highlight improved disease control, reduced eye bulging, and weight-loss benefits, potentially broadening options for patients with unmet needs.
|Articles|October 1, 2015
- BioPharm International-10-01-2015
- Volume 28
- Issue 10
BioPharm International, October 2015 Issue (PDF)
Click the title above to open the BioPharm International October 2015 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 11 years ago
A Review of Glycan Analysis Requirementsabout 11 years ago
Evolving to Meet Industry Changesabout 11 years ago
Small-Molecule API CMOs Are Thrivingabout 11 years ago
Small-Scale and At-Scale Model Development and Optimizationabout 11 years ago
Market Access in ChinaAdvertisement
Related to this article
Antisense oligonucleotides are reshaping drug design, from RNase H gapmers to inhaled delivery; this FAQ explains how they work and why trials still fail.
Bristol Myers Squibb's Nathan Pennell explains how the MRD endpoint supports accelerated approval in multiple myeloma without changing how clinicians monitor patients.
Once-weekly amylin analog petrelintide produced up to 9.2% weight loss at 28 weeks in adults with obesity and type 2 diabetes, Zealand Pharma reports.
Teprotumumab N01 (Sycume) reduced eye bulging in 60.4% of patients with chronic, inactive thyroid eye disease in a phase 3 trial.
Tecentriq plus chemotherapy gains FDA approval for stage III dMMR colon cancer after a phase 3 trial showed improved disease-free survival.
New clinical milestones, manufacturing investments, and regulatory incentives could help developers overcome barriers to delivering treatments for patients with rare diseases.
Genglycos, the gene therapy that earned the voucher, will fund new Ultragenyx therapies for other rare and ultra-rare diseases.
Advertisement
Advertisement